Elsubrutinib,Upadacitinib,ABBV-599
AbbVie
['elsubrutinib', ' upa ', ' aa ', 'upadacitinib', 'lupus', 'sleek', 'pone ', 'abbv-599']
congress #eular2023 | joan t merrill presented phase ii sleek study data of abbv-599 (elsubrutinib and upadacitinib) vs upadacitinib monotherapy for #sle. the primary endpoint of sri-4 response was met at week 48 in both groups (51.5% for abbv-599 &amp; 45.2% for monotherapy). #lupus 
An online resource, dedicated to providing information and up-to-date medical education within the lupus space.